Showing 1 to 3 of 3 results


Wales Rolls Out Cancer Drug Doubling Survival Time
The NHS in Wales now provides capivasertib, a new breast cancer drug shown to double life expectancy for half of women with oestrogen-fueled breast cancer when combined with hormone therapy; developed by Velindre Cancer Centre and Cardiff University, it's a significant advancement offering extended ...
Wales Rolls Out Cancer Drug Doubling Survival Time
The NHS in Wales now provides capivasertib, a new breast cancer drug shown to double life expectancy for half of women with oestrogen-fueled breast cancer when combined with hormone therapy; developed by Velindre Cancer Centre and Cardiff University, it's a significant advancement offering extended ...
Progress
56% Bias Score


NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
Progress
36% Bias Score

NHS England Approves New Drug for Advanced Breast Cancer
A new drug, capivasertib, is now available on the NHS in England to treat advanced breast cancer, offering a potential benefit to 3,000 women yearly by slowing disease progression and shrinking tumors; it targets the AKT protein and was approved after successful clinical trials showing it doubled th...

NHS England Approves New Drug for Advanced Breast Cancer
A new drug, capivasertib, is now available on the NHS in England to treat advanced breast cancer, offering a potential benefit to 3,000 women yearly by slowing disease progression and shrinking tumors; it targets the AKT protein and was approved after successful clinical trials showing it doubled th...
Progress
40% Bias Score
Showing 1 to 3 of 3 results